Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: Efficacy of first-line treatments in the elderly and non-elderly patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: a network meta-analysis

Fig. 4

Pooled estimates of the network meta-analysis. Data in each cell are hazard or odds ratios (95% credible intervals) for the comparison of row-defining treatment versus column-defining treatment. Hazard ratios less than 1 and odds ratios more than 1 favor row-defining treatment. Significant results are in bold. PFS: progression free survival, OS: overall survival. A) Pooled odds ratios (95% credible intervals) for PFS in all patients. B) Pooled odds ratios (95% credible intervals) PFS in patients aged below 65 years. C) Pooled odds ratios (95% credible intervals) PFS in patients aged over 65 years. D) Pooled odds ratios (95% credible intervals) OS in all patients. E) Pooled odds ratios (95% credible intervals) OS in patients aged below 65 years. F) Pooled odds ratios (95% credible intervals) OS in patients aged over 65 years

Back to article page